



Dyrenium[®] (triamterene) – First-time generic

- On August 21, 2019, TruPharma launched an [AB-rated](#) generic version of Concordia's [Dyrenium \(triamterene\)](#) capsules.
- Dyrenium is approved for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism.
- Triamterene is also available generically in combination with [hydrochlorothiazide](#) for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone and for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked.
- Dyrenium carries a boxed warning for abnormal elevation of serum potassium levels.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.